APCCC 2019: Synthesis — Optimal Treatment of Men with Newly Diagnosed Prostate Cancer – Philippine Endourological Society
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis - European Urology Focus
EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis
Triplet Therapy Has a Place in Metastatic Hormone-Sensitive Prostate Cancer Treatment, But For Whom?
Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Cases - Synchronous Low Volume mHSPC
Metastatic Prostate Cancer: Sorting Through the Treatment Maze - The ASCO Post
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? - The Lancet Oncology
Treatment of Metastatic Prostate Cancer in 2018.,JAMA Oncology - X-MOL
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer - ScienceDirect
The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer | Journal of Urology
Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial | BMJ Open
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis - European Urology Focus
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
Patients' distribution according to LATITUDE and CHAARTED risk criteria... | Download Scientific Diagram
Impact of high-volume disease in Asian population with newly diagnosed metastatic prostate cancer Cheng YT, Hong JH, Lu YC, Pu YS, Huang CY, Huang KH, Liu SP, Chen CH - Urol Sci
Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference - YouTube
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact | Nature Communications
Surgical management of high-risk, localized prostate cancer | Nature Reviews Urology
Prostate Cancer: Double VS triplet therapy in mHSPC - Urology Cheatsheets
Consultation Report Topic details 1. Summary 2. Background 3. Publication of consultation
Prostate Cancer Review
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand | Bentham Science
Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? | American Society of Clinical Oncology Educational Book
